AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market ...

A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

The London Stock Exchange has been battling to keep hold of companies and Julia Hoggett, the chief executive of the exchange, ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...